1,741 Shares in Novo Nordisk A/S (NYSE:NVO) Purchased by Lantz Financial LLC

Lantz Financial LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 1,741 shares of the company’s stock, valued at approximately $224,000.

A number of other institutional investors have also bought and sold shares of the business. CNB Bank purchased a new position in Novo Nordisk A/S during the fourth quarter worth about $26,000. Pacific Center for Financial Services increased its holdings in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock worth $25,000 after buying an additional 135 shares during the last quarter. Valued Wealth Advisors LLC purchased a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at approximately $28,000. Frank Rimerman Advisors LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $30,000. Finally, Tyler Stone Wealth Management grew its position in Novo Nordisk A/S by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after acquiring an additional 146 shares during the period. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $141.95 on Friday. The stock has a market capitalization of $637.00 billion, a price-to-earnings ratio of 48.95, a price-to-earnings-growth ratio of 1.40 and a beta of 0.41. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The business has a 50-day moving average of $132.94 and a 200 day moving average of $121.73. Novo Nordisk A/S has a 12 month low of $75.56 and a 12 month high of $144.50.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.77 by $0.06. The business had revenue of $9.52 billion for the quarter, compared to analysts’ expectations of $9.23 billion. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on NVO shares. Argus lifted their target price on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, June 10th. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, June 17th. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research report on Thursday, May 30th. They issued a “buy” rating and a $156.00 target price on the stock. Finally, BMO Capital Markets assumed coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price target for the company. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and a consensus target price of $145.67.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.